Driving the Future of Sales Enablement

October 16-18, 2019 | USA

In this session you will be taken on a journey that includes the sharing of strategies and tactics that were used to establish critical relationships resulting in new levels of executive collaboration and engagement that transformed one Sales Enablement organization from a relatively unknown entity into a critical and globally recognized function within a Fortune 100 company. From one practitioner to another, learn and discuss real-life strategies and tactics that you can adopt right away, including.
Driving the Future of Sales Enablement: Re-Imagining How People, Experience and Technology Drive Growth in the Digital Economy.

Spotlight

Dr. Chris Leptak of the FDA’s Center for Drug Evaluation and Research discusses the three primary sources for biomarker evidence use by FDA to inform regulatory decisions – scientific community consensus, drug-specific development and approval process, and CDER’s Biomarker Qualification Program. No matter which pathway the drug developer selects, consulting with the FDA is a critical step to achieve success.


OTHER PAST CONFERENCES

IDN & Bio/Pharma Partnering Summit

August 16-17, 2022 | USA

A think-tank for industry pioneers, showcasing novel case studies and innovative partnership models that deliver enhanced value, manage costs and improve quality

Drug Delivery and Nanomedicine

July 18-20, 2022 | USA

After a successful Drug Delivery Webinar 2021 during March and August 2021. it is our greatest pleasure to welcome you to the 5th Edition of Drug Delivery Webinar planned to be organized during July 18-20, 2022.

REIMAGINING THE MEETING PLANNING EXPERIENCE IN LIFE SCIENCES

September 11-14, 2022 | USA

Pharma Forum is the largest, most influential conference for Meeting & Event Professionals to navigate the future of medical meetings, address compliance implications and execute contracting strategies with virtual, hybrid, and face-to-face.

Drug Discovery And Communal Trial

August 27-28, 2022 | Malaysia

Association of Pharmaceutical Research (APR) organizes the “Pharma Summit 2022: Drug Discovery & Communal Trial” on 27th & 28th August 2022, in Kuala Lumpur, Malaysia.

Spotlight

Dr. Chris Leptak of the FDA’s Center for Drug Evaluation and Research discusses the three primary sources for biomarker evidence use by FDA to inform regulatory decisions – scientific community consensus, drug-specific development and approval process, and CDER’s Biomarker Qualification Program. No matter which pathway the drug developer selects, consulting with the FDA is a critical step to achieve success.

resources